Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8962618
SERIAL NO

13458452

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohdroxy pridines or primidines as diacylglycerol O-acyltransferase 1 DGAT-1 inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • METABASIS THERAPEUTICS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bookser, Brett C San Diego, US 20 68
Boyer, Serge H San Diego, US 16 312
Erion, Mark D Del Mar, US 67 1936
Hecker, Scott J Del Mar, US 49 281
Mali, Venkat Reddy Cupertino, US 55 216
Raffaele, Nicholas Brian San Diego, US 7 10
Reddy, K Raja San Diego, US 46 897
Stebbins, Jeff San Diego, US 4 5

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 24, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00